CDK4/6i
Medical abbreviation · Drug Class
| Stands for | Cyclin-dependent kinase 4/6 inhibitor |
|---|---|
| Categories | Medical |
CDK4/6i stands for Cyclin-dependent kinase 4/6 inhibitor, a drug class abbreviation.
Oral drugs, palbociclib, ribociclib and abemaciclib, that halt the cancer cell cycle. Combined with hormonal therapy, they are standard first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer.
Example: Letrozole plus CDK4/6i ribociclib 600 mg days 1-21 of 28; ECG for QTc.
Usage notes
Palbociclib (Ibrance), approved in 2015, was the first. Neutropenia is the main side effect of palbociclib and ribociclib, while abemaciclib more often causes diarrhea. Ribociclib requires ECG monitoring for QT prolongation. Abemaciclib and ribociclib are also approved to reduce recurrence after surgery in high-risk early breast cancer.
Related abbreviations
More drug class abbreviations
- BL/BLI – Beta-lactam/beta-lactamase inhibitor
- BTKi – Bruton tyrosine kinase inhibitor
- BZD – Benzodiazepine
- BZRA – Benzodiazepine receptor agonist
- CAI – Carbonic anhydrase inhibitor
- CCB – Calcium channel blocker
- CNI – Calcineurin inhibitor
- COC – Combined oral contraceptive
- COX-2 – Cyclooxygenase-2 selective inhibitor
- DHP – Dihydropyridine
- DMARD – Disease-modifying antirheumatic drug
- DOAC – Direct oral anticoagulant
See all 113 drug class abbreviations →
This entry is for general education and is not medical advice. Abbreviation use varies between institutions; always confirm in context.